Form 8-K - Current report:
SEC Accession No. 0000950170-25-095029
Filing Date
2025-07-10
Accepted
2025-07-10 16:30:30
Documents
11
Period of Report
2025-07-03
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tcrt-20250703.htm   iXBRL 8-K 143466
2 EX-3.1 tcrt-ex3_1.htm EX-3.1 14095
  Complete submission text file 0000950170-25-095029.txt   272959

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250703.xsd EX-101.SCH 26365
13 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250703_htm.xml XML 4708
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 251116611
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)